Moderna Inc MRNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
The science of vaccines is rapidly advancing - despite the anti-vax movement
Moderna raises its revenue outlook - but all eyes are on what happens next with its cancer vaccine
Moderna Swings to 3Q Profit, Lifts Outlook as Covid-19 Vaccine Demand Stabilizes — Update
Moderna Lifts Outlook, Swings to 3Q Profit
The excitement around Moderna's cancer vaccine is cooling. Here's why.
Moderna's cancer vaccine is 'likely' to get approved. Skeptics question if it will be the best option.
The stock market is splitting in two. Is that signaling trouble ahead, or just a new set of winners?
Moderna's cancer vaccine hits its targets, but a data leak rattled investors and the stock tumbled
Trading Information
- Previous Close Price
- €189.56
- Day Range
- €189.06–189.72
- 52-Week Range
- €19.48–246.70
- Bid/Ask
- €189.76 / €190.50
- Shares Outstanding
- 404.62M
- Market Cap
- €76.76B
- Volume/Avg
- — / 676
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 34.65
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 4,700
- Website
- https://www.modernatx.com
Competitors
Valuation
Metric | MRNA | BNTX | PFE |
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 13.10 |
Price/Book Value | 12.70 | 1.05 | 1.82 |
Price/Sales | 34.65 | 7.55 | 2.57 |
Price/Cash Flow | — | — | 11.04 |
Price/Earnings
MRNA
BNTX
PFE
Financial Strength
Metric | MRNA | BNTX | PFE |
|---|---|---|---|
Quick Ratio | 3.34 | 8.43 | 1.00 |
Current Ratio | 3.62 | 8.55 | 1.42 |
Interest Coverage | −49.00 | — | 2.39 |
Quick Ratio
MRNA
BNTX
PFE
Profitability
Metric | MRNA | BNTX | PFE |
|---|---|---|---|
Return on Assets (Normalized) | −20.21% | −3.31% | 8.49% |
Return on Equity (Normalized) | −31.30% | −3.78% | 19.73% |
Return on Invested Capital (Normalized) | −27.15% | −4.37% | 12.71% |
Return on Assets
MRNA
BNTX
PFE
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|xw%?r? | LOCK|T>Wj | $135B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|^WXbHn | LOCK|TK^Y | $99B | |||
| Moderna Inc MRNA | LOCK|<?HcN&# | LOCK|hL | $84B | |||
| argenx SE ADR ARGX | LOCK|n!Z$%? | LOCK|xQ& | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|<NtFRW | LOCK|cl< | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|%vf%@Vl | LOCK|M^D^ | $31B | |||
| Incyte Corp INCY | LOCK|h!mk!^ | LOCK|DD | $24B | |||
| BioNTech SE ADR BNTX | LOCK|pp&G>#s | LOCK|%% | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|$%@^Nhc | LOCK|p#YC | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|&H<c@? | LOCK|?s& | $15B |